Mechanism of drug resistance in non-small-cell lung cancer
This article has no abstract so we have provided the first paragraph of the full text.
A recent report by Kobayashi et al. sheds light on the mechanism of drug resistance in non-small-cell lung cancer patients who are initially responsive to anilinoquinazoline epidermal growth factor receptor (EGFR) inhibitors.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cancer Mixing cocktailsNature News and Views (25 Oct 2007)
Where lies the blame for resistance?tumor or host?Nature Medicine News and Views (01 Oct 2007)